The DOI matches its Crossref record; 76 of the 80 references it cites were found in a registry or an index.
Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19
Open accessPublished version of a preprint
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus is causing a global pandemic, and cases continue to rise. Most infected individuals experience mildly symptomatic coronavirus disease 2019 (COVID-19), but it is unknown whether this can induce persistent immune memory that could contribute to immunity. We performed a longitudinal assessment of individuals recovered from mild COVID-19 to determine whether they develop and sustain multifaceted SARS-CoV-2-specific immunological memory. Recovered individuals developed SARS-CoV-2-specific immunoglobulin (IgG) antibodies, neutralizing plasma, and memory B and memory T cells that persisted for at least 3 months. Our data further reveal that SARS-CoV-2-specific IgG memory B cells increased over time. Additionally, SARS-CoV-2-specific memory lymphocytes exhibited characteristics associated with potent antiviral function: memory T cells secreted cytokines and expanded upon antigen re-encounter, whereas memory B cells expressed receptors capable of neutralizing virus when expressed as monoclonal antibodies. Therefore, mild COVID-19 elicits memory lymphocytes that persist and display functional hallmarks of antiviral immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Among cytokine profiles of spike-responsive memory T cells, production was dominated by the expression of IL-2 and IFN-γ that were highly expressed by CCR6− subsets.32, 33”
From Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial (2022) · cites this paper as [33]
In the citing paper
“However, neutralizing antibody responses decay rapidly in early convalescence9,14–17.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [9]
In the citing paper
“We and others have shown that SARS-CoV-2-specific memory B cells accumulate over the first few months after initial infection2,3,8,9,28 (Fig. 1a)”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [9]
In the citing paper
“The observations that frequencies of circulating memory B cells continue to increase for several months after recovery from COVID-19 (refs2,3,8,9,28), when most other responses are declining (Fig. 1a), suggest that recall of B cell memory may provide a mechanism to extend the duration of antibody-dependent protection in the face of waning serological titres.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [9]
In the citing paper
“SARS-CoV-2 infection rapidly elicits nAbs (16, 21–24) that decline, but remain detectable, over several months (25–29).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [26]
In the citing paper
“SARS-CoV-2 infection can induce the production of neutralizing antibodies, and these antibodies are believed to contribute to protection from reinfection (Rodda et al., 2020; Wajnberg et al., 2020).”
From SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies (2021) · cites this paper as Rodda et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
Sallusto, F., Lenig, D., Förster, R., Lipp, M., & Lanzavecchia, A. (1999) · Nature · doi:10.1038/44385 · Cited by 5,846 · cited 1×
“Antigen-specific memory CD4 T cells proliferate to re-seed the memory pool and generate effector cells upon antigen reexposure (Sallusto et al., 1999).”
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Self-citationSARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
Le Bert, N., Tan, A. T., Kunasegaran, K., Tham, C. Y. L., Hafezi, M., Chia, A., Chng, M. H. Y., Lin, M., Tan, N., Linster, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2550-z · Cited by 1,887
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.-B., Olsson, A., Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.017 · Cited by 1,788
Immunological memory and protective immunity: understanding their relation
Ahmed, R., & Gray, D. (1996) · Science · doi:10.1126/science.272.5258.54 · Cited by 1,775 · cited 2×
“(legend continued on next page) ll Cell 184, 169–183, January 7, 2021 171 Article ll Article years, depending upon the specific viral infection (Slifka and Ahmed, 1996).”
Flagged first, then by citations
4 of the 80 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Nellore, 2019, Fcrl5 and T-bet define influenza-specific memory B cells that predict long-lived antibody responses, bioRxiv
- Wajnberg, 2020, SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months, medRxiv
Cited by
Sorted by citations
Items 101–200 of 644
The role of B cells in COVID-19 infection and vaccination
Chen, S., Guan, F., Candotti, F., Benlagha, K., Câmara, N. O. S., Herrada, A. A., James, L. K., Lei, J., Miller, H., Kubo, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.988536 · Cited by 75
Koerber, N., Priller, A., Yazici, S., Bauer, T., Cheng, C., Mijočević, H., Wintersteller, H., Jeske, S. D., Vogel, E., Feuerherd, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27649-y · Cited by 75
Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination
Altawalah, H. (2021) · Vaccines · doi:10.3390/vaccines9080910 · Cited by 74
Gagné, M., Corbett, K. S., Flynn, B. J., Foulds, K. E., Wagner, D. A., Andrew, S. F., Todd, J.-P. M., Honeycutt, C. C., McCormick, L., Nurmukhambetova, S. T., et al. (2021) · Cell · doi:10.1016/j.cell.2021.12.002 · Cited by 71
Lin, Y., Wang, G., Shen, Y., Wang, Z.-Y., Zhan, B.-D., Duan, L., Lu, B., Shi, C., Gao, Y., Peng, H.-H., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab255 · Cited by 69
Newell, K. L., Clemmer, D. C., Cox, J. B., Kayode, Y. I., Zoccoli-Rodriguez, V., Taylor, H. E., Endy, T. P., Wilmore, J. R., & Winslow, G. M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0244855 · Cited by 70
Bertoletti, A., Tan, A. T., & Bert, N. L. (2021) · Oxford Open Immunology · doi:10.1093/oxfimm/iqab006 · Cited by 69
Zhang, J., Lin, H., Ye, B., Zhao, M. J., Zhan, J., Dong, S., Guo, Y., Zhao, Y., Li, M., Liu, S., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab884 · Cited by 69
Waning antibody responses in COVID-19: what can we learn from the analysis of other coronaviruses?
Hamady, A., Lee, J., & Loboda, Z. (2021) · Infection · doi:10.1007/s15010-021-01664-z · Cited by 66
Evolution of antibody immunity following Omicron BA.1 breakthrough infection
Kaku, C. I., Starr, T. N., Zhou, P.-P., Dugan, H. L., Khalifé, P., Song, G., Champney, E. R., Mielcarz, D. W., Geoghegan, J. C., Burton, D. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38345-4 · Cited by 70
Harrington, W. E., Trakhimets, O., Andrade, D. V., Dambrauskas, N., Raappana, A., Jiang, Y., Houck, J., Selman, W., Yang, A., Vigdorovich, V. I., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100253 · Cited by 65
Instructing durable humoral immunity for COVID-19 and other vaccinable diseases
Bhattacharya, D. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.004 · Cited by 64
Immune responses in mildly versus critically ill COVID-19 patients
Nasrollahi, H., Talepoor, A. G., Saleh, Z., Vakili, M. E., Heydarinezhad, P., Karami, N., Noroozi, M., Meri, S., & Kalantar, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1077236 · Cited by 63
Dynamics of antibodies to SARS‐CoV‐2 in convalescent plasma donors
Steenhuis, M., van Mierlo, G. J., Derksen, N. I. L., Heer, P. O., Kruithof, S., Loeff, F. C., Berkhout, L. C., Linty, F., Reusken, C. B. E. M., Reimerink, J. H. J., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1285 · Cited by 63
Karim, F., Gazy, I., Cele, S., Zungu, Y., Krause, R., Bernstein, M. P., Khan, K., Ganga, Y., Rodel, H. E., Mthabela, N., et al. (2021) · eLife · doi:10.7554/elife.67397 · Cited by 64
Maringer, Y., Nelde, A., Schroeder, S. M., Schuhmacher, J., Hörber, S., Peter, A., Karbach, J., Jäger, E., & Walz, J. S. (2022) · Science Immunology · doi:10.1126/sciimmunol.add3899 · Cited by 62
Manisty, C., Treibel, T. A., Jensen, M. P., Semper, A. E., Joy, G., Gupta, R. K., Cutiño‐Moguel, T., Andiapen, M., Jones, J., Taylor, S. C., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103259 · Cited by 60
Trougakos, I. P., Terpos, E., Zirou, C., Sklirou, A. D., Apostolakou, F., Gumeni, S., Charitaki, I., Papanagnou, E., Bagratuni, T., Liacos, C., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02090-6 · Cited by 60
Feldman, J. E., Bals, J., Altomare, C. G., Denis, K. S., Lam, E. C., Hauser, B. M., Ronsard, L., Sangesland, M., Moreno, T. B., Okonkwo, V., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abl5842 · Cited by 60
Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients
Hashem, A. M., Algaissi, A. A., Almahboub, S. A., Alfaleh, M. A., Abujamel, T. S., Alamri, S. S., Alluhaybi, K. A., Hobani, H. I., Alharbi, R. H., Alsulaiman, R. M., et al. (2020) · Viruses · doi:10.3390/v12121390 · Cited by 58
Vick, S. C., Frutoso, M., Mair, F., Konecny, A., Greene, E., Wolf, C. R., Logue, J. K., Franko, N., Boonyaratanakornkit, J. B., Gottardo, R., et al. (2021) · Science Advances · doi:10.1126/sciadv.abj0274 · Cited by 58
Covid-19 vaccines: delivering protective immunity
Sewell, H. F., Agius, R. M., Kendrick, D., & Stewart, M. (2020) · BMJ · doi:10.1136/bmj.m4838 · Cited by 57
Durability of Immunity to SARS-CoV-2 and Other Respiratory Viruses
Siggins, M. K., Thwaites, R. S., & Openshaw, P. (2021) · Trends in Microbiology · doi:10.1016/j.tim.2021.03.016 · Cited by 61
Korosec, C. S., Farhang‐Sardroodi, S., Dick, D. W., Gholami, S., Ghaemi, M. S., Moyles, I. R., Craig, M., Ooi, H. K., & Heffernan, J. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-25134-0 · Cited by 59
Abebe, E. C., & Dejenie, T. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1055457 · Cited by 58
Ferreras, C., Pascual-Miguel, B., Mestre‐Durán, C., Navarro‐Zapata, A., Villa, L. C., Martín-Cortázar, C., de Paz, R., Marcos, A., Vicario, J., Balas, A., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.620730 · Cited by 55
Antibody Duration After Infection From SARS-CoV-2 in the Texas Coronavirus Antibody Response Survey
Swartz, M. D., DeSantis, S. M., Yaseen, A. S., Brito, F. A., Valerio-Shewmaker, M. A., Messiah, S. E., León‐Novelo, L., Kohl, H. W., Pinzon-Gomez, C. L., Hao, T., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac167 · Cited by 56
Favresse, J., Eucher, C., Elsen, M., Gillot, C., Eeckhoudt, S. V., Dogné, J., & Douxfils, J. (2021) · Microorganisms · doi:10.3390/microorganisms9030556 · Cited by 54
COVID‐19 immunopathology: From acute diseases to chronic sequelae
Arish, M., Qian, W. G., Narasimhan, H., & Sun, J. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28122 · Cited by 55
Role of T cells in severe COVID-19 disease, protection, and long term immunity
Hermens, J. M., & Keşmir, C. (2023) · Immunogenetics · doi:10.1007/s00251-023-01294-9 · Cited by 57
The way of SARS-CoV-2 vaccine development: success and challenges
Dong, Y., Dai, T., Wang, B., Zhang, L., Zeng, L., Huang, J., Yan, H., Zhang, L., & Zhou, F. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00796-w · Cited by 53
Nelson, R. W., Chen, Y., Venezia, O. L., Majerus, R. M., Shin, D. S., MGH COVID-19 Collection & Processing Team, Carrington, M. N., Yu, X. G., Wesemann, D. R., Moon, J. J., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abl9464 · Cited by 56
Self-citationByazrova, M. G., Yusubalieva, G. M., Spiridonova, A. A., Efimov, G. A., Mazurov, D. V., Baranov, K. O., Baklaushev, V. P., & Filatov, A. V. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1245 · Cited by 52
COVID-19: Molecular and Cellular Response
Alipoor, S. D., Mortaz, E., Jamaati, H., Tabarsi, P., Bayram, H., Varahram, M., & Adcock, I. M. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.563085 · Cited by 53
Sokal, A., Broketa, M., Barba-Spaeth, G., Meola, A., Fernández, I., Fourati, S., Azzaoui, I., de La Selle, A., Vandenberghe, A., Roeser, A., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.04.002 · Cited by 50
Sasikala, M., Jaggaiahgari, S., Gujjarlapudi, D., Ravikanth, V. V., Krishna, V. V., Yelamanchili, S., Kottapalli, P., & Reddy, D. N. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.05.034 · Cited by 50
Garrido, C., Hurst, J. H., Lorang, C. G., Aquino, J. N., Rodriguez, J., Pfeiffer, T. S., Singh, T., Semmes, E. C., Lugo, D. J., Rotta, A. T., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150909 · Cited by 51
Ha, E. K., Kim, J. H., & Han, M. Y. (2023) · Korean Journal of Pediatrics · doi:10.3345/cep.2023.00472 · Cited by 51
Ameratunga, R., Longhurst, H. J., Steele, R. H., Lehnert, K., Leung, E. Y., Brooks, A. E. S., & Woon, S. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.06.019 · Cited by 49
Lei, H., Alu, A., Yang, J., He, X., He, C., Ren, W., Chen, Z., Hong, W., Chen, L., He, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38066-8 · Cited by 49
Impaired Humoral Immunity Is Associated With Prolonged COVID-19 Despite Robust CD8 T-Cell Responses
Lyudovyk, O., Kim, J. Y., Qualls, D. A., Hwee, M. A., Lin, Y.-H., Boutemine, S. R., Elhanati, Y., Solovyov, A., Douglas, M., Chen, E., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.05.013 · Cited by 48
Mechanism of COVID-19 Causing ARDS: Exploring the Possibility of Preventing and Treating SARS-CoV-2
Zheng, J., Miao, J., Guo, R., Guo, J., Fan, Z., Kong, X., Gao, R., & Yang, L. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.931061 · Cited by 49
Makaronidis, J., Firman, C., Magee, C. G., Mok, J., Balogun, N., Lechner, M., Carnemolla, A., & Batterham, R. L. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-05927-w · Cited by 48
Cagigi, A., Yu, M., Österberg, B., Svensson, J., Falck‐Jones, S., Vangeti, S., Åhlberg, E., Azizmohammadi, L., Warnqvist, A., Falck‐Jones, R., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.151463 · Cited by 48
Self-citationIdentification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics
Nagler, A., Kalaora, S., Barbolin, C., Gangaev, A., Ketelaars, S. L. C., Alon, M., Pai, J. A., Benedek, G., Yahalom-Ronen, Y., Noam Erez, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109305 · Cited by 47
The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection
Moga, E., Lynton‐Pons, E., & Domingo, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.904686 · Cited by 48
Balachandran, H., Phetsouphanh, C., Agapiou, D., Adhikari, A., Rodrigo, C., Hammoud, M., Shrestha, L. B., Keoshkerian, E., Gupta, M., Turville, S. G., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110345 · Cited by 45
Sandberg, J. T., Varnaitė, R., Christ, W., Chen, P., Muvva, J. R., Maleki, K. T., García, M., Dzidic, M., Folkesson, E., Skagerberg, M., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1306 · Cited by 45
Identifying SARS‐CoV‐2 ‘memory’ NK cells from COVID‐19 convalescent donors for adoptive cell therapy
Herrera, L., Martin‐Inaraja, M., Santos, S. J., Inglés‐Ferrándiz, M., Azkarate, A., Pérez-Vaquero, M. Á., Vesga, M. Á., Vicario, J. L., Soria, B., Solano, C., et al. (2021) · Immunology · doi:10.1111/imm.13432 · Cited by 44
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
Ogbe, A., Pace, M. J., Bittaye, M., Tipoe, T., Adele, S., Alagaratnam, J., Aley, P. K., Ansari, M. A., Bara, A., Broadhead, S., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.157031 · Cited by 44
COVID ‐19 and plasma cells: Is there long‐lived protection?*
Nguyen, D. C., Lamothe, P. A., Woodruff, M. C., Saini, A. S., Faliti, C. E., Sanz, I., & Lee, F. E.-H. (2022) · Immunological Reviews · doi:10.1111/imr.13115 · Cited by 48
SARS-CoV-2—The Role of Natural Immunity: A Narrative Review
Diani, S., Leonardi, E. A., Cavezzi, A., Ferrari, S., Iacono, O., Limoli, A., Bouslenko, Z., Natalini, D., Conti, S., Mantovani, M., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11216272 · Cited by 44
Chen, J., Liu, X., Zhang, X., Lin, Y., Liu, D., Xun, J., Wang, Z., Gu, L., Li, Q., Yin, D., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1319 · Cited by 44
T cell perturbations persist for at least 6 months following hospitalization for COVID-19
Govender, M., Hopkins, F. R., Göransson, R., Svanberg, C., Shankar, E. M., Hjorth, M., Nilsdotter‐Augustinsson, Å., Sjöwall, J., Nyström, S. N., & Larsson, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.931039 · Cited by 43
Testing Fractional doses of COVID-19 Vaccines
Więcek, W., Ahuja, A., Chaudhuri, E., Kremer, M. R., Gomes, A. S., Snyder, C. M., Tabarrok, A. T., & Tan, B. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2116932119 · Cited by 43
Early human B cell signatures of the primary antibody response to mRNA vaccination
Kardava, L., Rachmaninoff, N., Lau, W. W., Buckner, C. M., Trihemasava, K., de Assis, F. L., Wang, W., Zhang, X., Wang, Y., Chiang, C.-I., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204607119 · Cited by 43
IgM antibodies derived from memory B cells are potent cross-variant neutralizers of SARS-CoV-2
Hale, M. R., Netland, J., Chen, Y., Thouvenel, C. D., Smith, K. N., Rich, L. M., Vanderwall, E. R., Miranda, M. C., Eggenberger, J., Hao, L., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220849 · Cited by 43
Self-citationSARS-CoV-2 accessory proteins reveal distinct serological signatures in children
Hachim, A., Gu, H., Kavian, O., Mori, M., Kwan, M. Y. W., Chan, W. H., Yau, Y. S., Chiu, S. S., Tsang, O. T. Y., Hui, D. S. C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30699-5 · Cited by 42
Tang, B., Tang, L., He, W., Jiang, X., Hu, C.-J., Li, Y., Zhang, Y., Pang, K., Lei, Y., Li, S., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100752 · Cited by 42
Fazolo, T., Lima, K. R., da Fontoura, J. C., de Souza, P. O., Hilario, G., Zorzetto, R., Júnior, L. R., Pscheidt, V. M., Neto, J. D. C. F., Haubert, A. F., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27120-y · Cited by 40
Zhu, A., Chen, Z., Yan, Q., Jiang, M., Liu, X., Li, Z., Li, N., Tang, C., Jian, W., He, J., et al. (2025) · Nature Immunology · doi:10.1038/s41590-024-02072-9 · Cited by 40
Self-citationCutting Edge: Distinct B Cell Repertoires Characterize Patients with Mild and Severe COVID-19
Hoehn, K. B., Ramanathan, P., Unterman, A., Sumida, T. S., Asashima, H., Hafler, D. A., Kaminski, N., Cruz, C. S. D., Sealfon, S. C., Bukreyev, A. A., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100135 · Cited by 40
RBD-Modified Bacterial Vesicles Elicited Potential Protective Immunity against SARS-CoV-2
Yang, Z., Hua, L., Yang, M., Liu, S.-Q., Shen, J., Li, W., Long, Q., Bai, H., Yang, X., Ren, Z., et al. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c00680 · Cited by 40
Self-citationT cell responses to SARS-CoV-2 in people with and without neurologic symptoms of long COVIDPreprint
Visvabharathy, L., Hanson, B. A., Orban, Z. S., Lim, P. H., Palacio, N. M., Jimenez, M., Clark, J. R., Graham, E. L., Liotta, E. M., Tachas, G., et al. (2021) · medRxiv · doi:10.1101/2021.08.08.21261763 · Cited by 40
Ferretti, F., Cannatelli, R., Benucci, M., Carmagnola, S., Clementi, E., Danelli, P., Dilillo, D., Fiorina, P., Galli, M., Gallieni, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.656362 · Cited by 39
Baumjohann, D., & Fazilleau, N. (2021) · European Journal of Immunology · doi:10.1002/eji.202049148 · Cited by 40
Christie, M. J., Irving, A. T., Forster, S. C., Marsland, B. J., Hansbro, P. M., Hertzog, P. J., Nold‐Petry, C. A., & Nold, M. F. (2021) · Science Immunology · doi:10.1126/sciimmunol.abd0205 · Cited by 41
What level of neutralising antibody protects from COVID-19?
Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K., Kent, S. J., Triccas, J. A., & Davenport, M. P. (2021) · doi:10.1101/2021.03.09.21252641 · Cited by 3,742
COVID-19 spread, detection, and dynamics in Bogota, Colombia
Laajaj, R., De Los Rios, C., Sarmiento-Barbieri, I., Aristizabal, D., Behrentz, E., Bernal, R., Buitrago, G., Cucunubá, Z., de la Hoz, F., Gaviria, A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25038-z · Cited by 38
Serum NGF and BDNF in Long-COVID-19 Adolescents: A Pilot Study
Petrella, C., Nenna, R., Petrarca, L., Tarani, F., Paparella, R., Mancino, E., Mattia, G. D., Conti, M. G., Matera, L., Bonci, E., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12051162 · Cited by 38
The Global Impact of COVID-19: A Comprehensive Analysis of Its Effects on Various Aspects of Life
Naveed, N., Ahmad, K., Majeed, H., Qureshi, K., Ahmad, I. S., Awan, M. F., Iftikhar, T., Ahmad, S., Noreen, F., Amin, M. A., et al. (2024) · Toxicology Research · doi:10.1093/toxres/tfae045 · Cited by 37
Zhao, W., Chen, W., Li, J., Chen, M., Li, Q., Lv, M., Zhou, S., Bai, S., Wang, Y., Zhang, L., et al. (2022) · mBio · doi:10.1128/mbio.00181-22 · Cited by 37
A Single Vaccine Protects against SARS-CoV-2 and Influenza Virus in Mice
Cao, K., Wang, X., Peng, H., Ding, L., Wang, X., Hu, Y., Dong, L., Yang, T., Hong, X., Xing, M., et al. (2021) · Journal of Virology · doi:10.1128/jvi.01578-21 · Cited by 37
T follicular helper cells in the humoral immune response to SARS-CoV-2 infection and vaccination
Koutsakos, M., Lee, W. S., Wheatley, A. K., Kent, S. J., & Juno, J. A. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.5mr0821-464r · Cited by 37
Jeffery-Smith, A., Burton, A. R., Lens, S., Rees-Spear, C., Davies, J. E., Patel, M., Gopal, R., Muir, L., Aiano, F., Doores, K. J., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci152042 · Cited by 37
Mechanistic Insights Into the Immune Pathophysiology of COVID-19; An In-Depth Review
Shafqat, A., Shafqat, S., Alsalameh, S., Kashir, J., AlKattan, K. M., & Yaqinuddin, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835104 · Cited by 37
Khairullin, B. M., Zakarya, K. D., Orynbayev, M. B., Abduraimov, Y. O., Kassenov, M., Sarsenbayeva, G., Sultankulova, K. T., Chervyakova, O. V., Myrzakhmetova, B. S., Куралбаевич, Н. А., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101526 · Cited by 36
Duan, C., Ma, R., Zeng, X., Chen, B., Hou, D., Liu, R., Li, X., Liu, L., Li, T., & Huang, H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.946731 · Cited by 36
Shi, Y., Huang, J., Liu, Y., Liu, J., Guo, X., Li, J., Gong, L., Zhou, X., Cheng, G., Qiu, Y., et al. (2022) · Science Advances · doi:10.1126/sciadv.abo1827 · Cited by 36
van der Ploeg, K., Kirosingh, A. S., Mori, D. A., Chakraborty, S., Hu, Z., Sievers, B. L., Jacobson, K. B., Bonilla, H. F., Parsonnet, J., Andrews, J. R., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100640 · Cited by 36
Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency
Heitmann, J. S., Tandler, C., Marconato, M., Nelde, A., Habibzada, T., Rittig, S. M., Tegeler, C. M., Maringer, Y., Jaeger, S. U., Denk, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40758-0 · Cited by 37
Olfactory immune response to SARS-CoV-2
Wellford, S. A., & Moseman, E. A. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01119-5 · Cited by 36
Simnani, F. Z., Singh, D., & Kaur, R. (2021) · 3 Biotech · doi:10.1007/s13205-021-03076-0 · Cited by 35
Differential Antibody Response to Inactivated COVID-19 Vaccines in Healthy Subjects
Zhang, J., Xing, S., Liang, D., Hu, W. G., Ke, C., He, J., Yuan, R., Huang, Y., Li, Y., Liu, D., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.791660 · Cited by 34
Perception, Prevalence, and Prediction of Severe Infection and Post-acute Sequelae of COVID-19
Knight, D. R. T., Munipalli, B., Logvinov, I. I., Halkar, M. G., Mitri, G., Dabrh, A. M. A., & Hines, S. L. (2022) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2022.01.002 · Cited by 35
CD8+ T Cells in SARS-CoV-2 Induced Disease and Cancer—Clinical Perspectives
Mortezaee, K., & Majidpoor, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864298 · Cited by 34
Sokal, A., Spaeth, G. B., Hunault, L., Fernández, I., Broketa, M., Meola, A., Fourati, S., Azzaoui, I., Vandenberghe, A., Lagouge-Roussey, P., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.07.007 · Cited by 37
B lymphocytes in COVID-19: a tale of harmony and discordance
Mansourabadi, A. H., Aghamajidi, A., Dorfaki, M., Keshavarz, F., Shafeghat, Z., Moazzeni, A., Arab, F. L., Rajabian, A., Roozbehani, M., Falak, R., et al. (2023) · Archives of Virology · doi:10.1007/s00705-023-05773-y · Cited by 35
Specific COVID-19 Symptoms Correlate with High Antibody Levels against SARS-CoV-2
Amjadi, M. F., O’Connell, S. E., Armbrust, T., Mergaert, A. M., Narpala, S., Halfmann, P., Bashar, S. J., Glover, C. R., Heffron, A. S., Taylor, A., et al. (2021) · ImmunoHorizons · doi:10.4049/immunohorizons.2100022 · Cited by 34
Severe acute respiratory syndrome coronavirus 2 causes lung inflammation and injury
Wang, L., Yang, J., & Xu, J. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.11.022 · Cited by 34
Molodtsov, I. A., Kegeles, E., Mitin, A. N., Mityaeva, O. N., Musatova, O. E., Panova, A. E., Pashenkov, M. V., Peshkova, I. O., Alsalloum, A., Asaad, W., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac278 · Cited by 33
Frailty impacts immune responses to Moderna COVID-19 mRNA vaccine in older adults
Semelka, C., DeWitt, M., Blevins, M. W., Holbrook, B. C., Sanders, J. W., & Alexander‐Miller, M. A. (2023) · Immunity & Ageing · doi:10.1186/s12979-023-00327-x · Cited by 35
Ford, E. S., Mayer-Blackwell, K., Jing, L., Laing, K. J., Sholukh, A. M., Germain, R. S., Bossard, E. L., Xie, H. J., Pulliam, T. H., Jani, S., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01692-x · Cited by 34
The intestinal microbiota and improving the efficacy of COVID-19 vaccinations
Chen, J., Vitetta, L., Henson, J. D., & Hall, S. (2021) · Journal of Functional Foods · doi:10.1016/j.jff.2021.104850 · Cited by 32
Reyes, R. A., Clarke, K., Gonzales, S. J., Cantwell, A. M., Garza, R., Catano, G., Tragus, R. E., Patterson, T. F., Bol, S. M., & Bunnik, E. M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0261656 · Cited by 33
Children and Adults With Mild COVID-19: Dynamics of the Memory T Cell Response up to 10 Months
Kaaijk, P., Pimentel, V. O., Emmelot, M. E., Poelen, M. C. M., Çevirgel, A., Schepp, R. M., den Hartog, G., Reukers, D. F. M., Beckers, L., van Beek, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.817876 · Cited by 32
Geanes, E. S., LeMaster, C., Fraley, E., Khanal, S., McLennan, R., Grundberg, E., Selvarangan, R., & Bradley, T. (2022) · Scientific Reports · doi:10.1038/s41598-022-10230-y · Cited by 33
Cardiovascular and Renal Risk Factors and Complications Associated With COVID-19
Touyz, R. M., Boyd, M. O. E., Guzik, T. J., Padmanabhan, S., McCallum, L., Delles, C., Mark, P. B., Petrie, J. R., Rios, F. J. O., Montezano, A. C. I., et al. (2021) · CJC Open · doi:10.1016/j.cjco.2021.05.020 · Cited by 34
Menges, D., Zens, K. D., Ballouz, T., Caduff, N., Llanas-Cornejo, D., Aschmann, H. E., Domenghino, A., Pellaton, C., Perreau, M., Fenwick, C. W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32573-w · Cited by 32
Pratama, N. R., Wafa, I. A., Budi, D. S., Sutanto, H., Asmarawati, T. P., Barlian Effendi, G., & Wungu, C. D. K. (2022) · Vaccines · doi:10.3390/vaccines10122180 · Cited by 30
Metadata
- Authors
- Rodda, L. B., Netland, J., Shehata, L., Pruner, K. B., Morawski, P. A., Thouvenel, C. D., Takehara, K. K., Eggenberger, J., Hemann, E. A., Waterman, H. R., Fahning, M. L., Chen, Y., Hale, M., Rathe, J., Stokes, C., Wrenn, S., Fiala, B., Carter, L., Hamerman, J. A., King, N. P., Gale, M., Campbell, D. J., Rawlings, D. J., & Pepper, M.
- Affiliations
- University of Washington (US)
- Benaroya Research Institute (US)
- Corresponding author
- Pepper, Marion
- ORCID
- Rodda, Lauren B.
- Netland, Jason
- Shehata, Laila
- Pruner, Kurt B.
- Morawski, Peter A.
- Thouvenel, Christopher D.
- Takehara, Kennidy K.
- Eggenberger, Julie
- Hemann, Emily A.
- Waterman, Hayley R.
- Fahning, Mitchell L.
- Chen, Yu
- Hale, Malika
- Stokes, Caleb
- Wrenn, Samuel
- Fiala, Brooke
- Carter, Lauren
- Hamerman, Jessica A.
- King, Neil P.
- Gale, Michael
- Campbell, Daniel J.
- Rawlings, David J.
- Pepper, Marion
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 184
- Issue
- 1
- Pages
- 169-183.e17
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC7682481
- OpenAlex
- W3107730772
- Cited by
- 647
- References
- 80
- Citations by year
- 2026: 10 · 2025: 30 · 2024: 46 · 2023: 85 · 2022: 171 · 2021: 278
- FWCI
- 18.44
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- medRxiv (acceptedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion)
- Funders
- National Institutes of Health
- Burroughs Wellcome Fund
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, mild COVID-19, immunological memory, memory B cells, memory T cells, neutralizing antibodies, IgG, long-term immunity, cytokine production, monoclonal antibodies, antiviral immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
